Qiagen Nv (QGEN)

$43.94

+1.7

(+4.02%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $42.87
    $44.08
    $43.94
    downward going graph

    2.44%

    Downside

    Day's Volatility :2.75%

    Upside

    0.32%

    downward going graph
  • $34.77
    $47.75
    $43.94
    downward going graph

    20.87%

    Downside

    52 Weeks Volatility :27.18%

    Upside

    7.98%

    downward going graph

Returns

PeriodQiagen NvSector (Health Care)Index (Russel 2000)
3 Months
1.42%
6.5%
0.0%
6 Months
-7.12%
7.1%
0.0%
1 Year
-13.29%
9.8%
0.0%
3 Years
-20.06%
14.2%
-20.2%

Highlights

Market Capitalization
9.3B
Book Value
$16.23
Dividend Share
0.0
Dividend Yield
2.94%
Earnings Per Share (EPS)
1.52
PE Ratio
27.64
PEG Ratio
1.25
Wall Street Target Price
49.71
Profit Margin
17.38%
Operating Margin TTM
21.41%
Return On Assets TTM
4.56%
Return On Equity TTM
9.41%
Revenue TTM
1.9B
Revenue Per Share TTM
8.73
Quarterly Revenue Growth YOY
-5.5%
Gross Profit TTM
1.4B
EBITDA
636.9M
Diluted Eps TTM
1.52
Quarterly Earnings Growth YOY
-0.06
EPS Estimate Current Year
2.12
EPS Estimate Next Year
2.29
EPS Estimate Current Quarter
0.44
EPS Estimate Next Quarter
0.52

Analyst Recommendation

Buy
    60%Buy
    40%Hold
    0
    0%Sell
Based on 25 Wall street analysts offering stock ratings for Qiagen Nv(by analysts ranked 0 to 5 stars)
Based on 25 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
14
Hold
10
10
10
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 13.13%

Current $43.94
Target $49.71

Company Financials

FY18Y/Y Change
Revenue
1.5B
↑ 5.95%
Net Income
190.4M
↑ 371.31%
Net Profit Margin
12.68%
↑ 9.83%
FY19Y/Y Change
Revenue
1.5B
↑ 1.64%
Net Income
-41.5M
↓ 121.77%
Net Profit Margin
-2.72%
↓ 15.4%
FY20Y/Y Change
Revenue
1.9B
↑ 22.53%
Net Income
73.6M
↓ 277.64%
Net Profit Margin
3.94%
↑ 6.66%
FY21Y/Y Change
Revenue
2.3B
↑ 20.39%
Net Income
512.6M
↑ 596.09%
Net Profit Margin
22.77%
↑ 18.83%
FY22Y/Y Change
Revenue
2.1B
↓ 4.89%
Net Income
423.2M
↓ 17.44%
Net Profit Margin
19.76%
↓ 3.01%
FY23Y/Y Change
Revenue
2.0B
↓ 8.23%
Net Income
341.3M
↓ 19.35%
Net Profit Margin
17.37%
↓ 2.39%
Q4 FY22Q/Q Change
Revenue
498.0M
↓ 0.33%
Net Income
88.8M
↑ 7.83%
Net Profit Margin
17.84%
↑ 1.35%
Q1 FY23Q/Q Change
Revenue
485.4M
↓ 2.53%
Net Income
85.0M
↓ 4.29%
Net Profit Margin
17.52%
↓ 0.32%
Q2 FY23Q/Q Change
Revenue
494.9M
↑ 1.95%
Net Income
80.8M
↓ 5.0%
Net Profit Margin
16.33%
↓ 1.19%
Q3 FY23Q/Q Change
Revenue
475.9M
↓ 3.83%
Net Income
77.8M
↓ 3.67%
Net Profit Margin
16.35%
↑ 0.02%
Q4 FY23Q/Q Change
Revenue
509.2M
↑ 6.99%
Net Income
97.7M
↑ 25.5%
Net Profit Margin
19.18%
↑ 2.83%
Q1 FY24Q/Q Change
Revenue
458.8M
↓ 9.89%
Net Income
80.7M
↓ 17.4%
Net Profit Margin
17.58%
↓ 1.6%
FY18Y/Y Change
Total Assets
5.7B
↑ 14.09%
Total Liabilities
3.1B
↑ 24.66%
FY19Y/Y Change
Total Assets
5.2B
↓ 8.92%
Total Liabilities
2.7B
↓ 13.31%
FY20Y/Y Change
Total Assets
6.0B
↑ 14.05%
Total Liabilities
3.5B
↑ 29.24%
FY21Y/Y Change
Total Assets
6.1B
↑ 2.94%
Total Liabilities
3.1B
↓ 12.55%
FY22Y/Y Change
Total Assets
6.3B
↑ 2.29%
Total Liabilities
2.8B
↓ 7.52%
FY23Y/Y Change
Total Assets
6.1B
↓ 2.74%
Total Liabilities
2.3B
↓ 18.21%
Q4 FY22Q/Q Change
Total Assets
6.3B
↓ 3.51%
Total Liabilities
2.8B
↓ 11.53%
Q1 FY23Q/Q Change
Total Assets
6.3B
↓ 0.14%
Total Liabilities
2.7B
↓ 3.66%
Q2 FY23Q/Q Change
Total Assets
6.3B
↑ 1.09%
Total Liabilities
2.7B
↑ 0.22%
Q3 FY23Q/Q Change
Total Assets
5.9B
↓ 6.94%
Total Liabilities
2.2B
↓ 18.75%
Q4 FY23Q/Q Change
Total Assets
6.1B
↑ 3.53%
Total Liabilities
2.3B
↑ 4.27%
Q1 FY24Q/Q Change
Total Assets
5.8B
↓ 5.06%
Total Liabilities
2.2B
↓ 4.38%
FY18Y/Y Change
Operating Cash Flow
359.5M
↑ 25.36%
Investing Cash Flow
-211.4M
↓ 54.48%
Financing Cash Flow
360.4M
↓ 6.92%
FY19Y/Y Change
Operating Cash Flow
330.8M
↓ 7.97%
Investing Cash Flow
-222.3M
↑ 5.17%
Financing Cash Flow
-639.1M
↓ 277.32%
FY20Y/Y Change
Operating Cash Flow
492.3M
↑ 48.79%
Investing Cash Flow
-443.3M
↑ 99.43%
Financing Cash Flow
-74.3M
↓ 88.37%
FY21Y/Y Change
Operating Cash Flow
639.0M
↑ 29.81%
Investing Cash Flow
-202.4M
↓ 54.33%
Financing Cash Flow
-150.4M
↑ 102.32%
FY22Y/Y Change
Operating Cash Flow
715.3M
↑ 11.93%
Investing Cash Flow
-735.6M
↑ 263.38%
Financing Cash Flow
-125.8M
↓ 16.34%
Q4 FY22Q/Q Change
Operating Cash Flow
124.3M
↓ 41.24%
Investing Cash Flow
-133.3M
↑ 200.01%
Financing Cash Flow
-546.4M
↓ 233.91%
Q1 FY23Q/Q Change
Operating Cash Flow
71.9M
↓ 42.14%
Investing Cash Flow
156.3M
↓ 217.2%
Financing Cash Flow
-9.8M
↓ 98.2%
Q2 FY23Q/Q Change
Operating Cash Flow
111.5M
↑ 54.99%
Investing Cash Flow
156.3M
↑ 0.0%
Financing Cash Flow
-15.5M
↑ 57.43%
Q3 FY23Q/Q Change
Operating Cash Flow
124.7M
↑ 11.85%
Investing Cash Flow
248.4M
↑ 58.93%
Financing Cash Flow
-401.1M
↑ 2492.37%

Technicals Summary

Sell

Neutral

Buy

Qiagen Nv is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Qiagen Nv
Qiagen Nv
3.71%
-7.12%
-13.29%
-20.06%
6.97%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-3.67%
-10.34%
-15.37%
-31.35%
65.77%
Agilent Technologies Inc.
Agilent Technologies Inc.
1.42%
3.05%
5.07%
-10.16%
94.22%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
6.51%
8.62%
3.5%
12.36%
106.99%
Danaher Corp.
Danaher Corp.
6.51%
15.92%
1.97%
-6.92%
89.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
10.0%
7.5%
0.14%
-6.07%
45.29%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Qiagen Nv
Qiagen Nv
27.64
27.64
1.25
2.12
0.09
0.05
0.03
16.23
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
45.67
45.67
4.75
11.06
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
31.63
31.63
2.7
5.2
0.21
0.08
0.01
21.31
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.72
35.72
2.81
21.71
0.14
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
48.76
48.76
3.13
6.99
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
30.13
30.13
1.33
11.19
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Qiagen Nv
Qiagen Nv
Buy
$9.3B
6.97%
27.64
17.38%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$38.8B
65.77%
45.67
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.9B
94.22%
31.63
18.84%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$219.4B
106.99%
35.72
14.2%
Danaher Corp.
Danaher Corp.
Buy
$191.9B
89.83%
48.76
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.3B
45.29%
30.13
9.39%

Insights on Qiagen Nv

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 509.16M → 458.79M (in $), with an average decrease of 9.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 97.66M → 80.67M (in $), with an average decrease of 17.4% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 5.1% return, outperforming this stock by 18.4%

  • Vs TMO

    In the last 3 years, Qiagen Nv has experienced a drawdown of -20.1%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 9.9%

Institutional Holdings

  • Massachusetts Financial Services Company

    10.48%

  • Wellington Management Company LLP

    4.29%

  • Vanguard Group Inc

    3.91%

  • BlackRock Inc

    3.44%

  • Amundi

    3.11%

  • Mariner Value Strategies, LLC

    2.03%

Corporate Announcements

  • Qiagen Nv Dividends March,2024

    In the quarter ending March,2024. Qiagen Nv has declared dividend of $1.28

    Read More

Company Information

qiagen is the leading global provider of sample to insight solutions to transform biological materials into valuable molecular insights. qiagen sample technologies isolate and process dna, rna and proteins from blood, tissue and other materials. assay technologies make these biomolecules visible and ready for analysis. bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. automation solutions tie these together in seamless and cost-effective molecular testing workflows. qiagen provides these workflows to more than 500,000 customers around the world in molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing and food safety), pharma (pharmaceutical and biotechnology companies) and academia (life sciences research). as of june 30, 2015, qiagen employed approximately 4,400 people in over 35 locations worldwide. further information can be found at http://www.qiagen.com.

Organization
Qiagen Nv
Employees
5900
CEO
Mr. Thierry Bernard
Industry
Health Technology

Discover More

FAQs